Earnings Call · Q2 FY2023·2023-08-03

Q2 23EPS +7.14%·Rev n/aQ1 23EPS +22.22%·Rev n/aQ4 22EPS -7.69%·Rev n/aQ3 22EPS +11.11%·Rev n/a⚠ consensus missing

Arbutus Biopharma Corp ABUS

Lisa Caperelli — Investor Relations or Corporate Communications

Bill Collier — President and Chief Executive Officer

Karen Sims — Chief Medical Officer

David Hastings — Chief Financial Officer

−2.9%1d on move date−2.4% vs SPY3d−1.2%5d−8.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ABUS calls or request research access.

More ABUS calls Browse calls Request research access